ALFA Finder| Revenue growth | 34% YoY |
|---|---|
| Margins | Blended EBITDA margin improved significantly to 15.25% |
| Order book | Rs. 58 Cr initial CDMO dispatches completed |
| Demand visibility | Strong; Rs. 825 Cr CDMO mandate entering commercial supply |
| Management confidence | High; citing 'Commercial Validation' of 2.0 strategy |
Growth
Revenue grew 34% YoY to Rs. 575.31 Cr; PAT surged 394% to Rs. 56.35 Cr. API exports up 42%.
Outlook
Major capacity expansion planned from 600 KL to 1200 KL by FY30. CDMO mandate valued at Rs. 825 Cr.
Risks
Transition from transaction-based business; scaling manufacturing capacity to meet global demand across four expansion phases.
Investor Presentation filed with BSE, NSE: MOREPENLAB. Summary written with AI assistance from the document.
Morepen Laboratories Ltd: key numbers
- Share price
- ₹99.64
- Market cap
- ₹5,460 Cr
- Revenue (annual)
- ₹1,806 Cr
- Net profit (annual)
- ₹94.88 Cr
- P/E (TTM)
- 29.0×Sector 43.7×
- Promoter holding
- 35.65%+0.00% QoQ
- FII holding
- 3.43%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Morepen Laboratories Ltd
All →Morepen Laboratories Credit Rating
Morepen Laboratories' bank facilities were upgraded by Infomerics to IVR A/ Stable. The upgrade follows the rating agency's letter dated 13 November 2026.
Morepen Laboratories Product Launch
Morepen launched Desloratadine Tablets USP 5 mg, its first US prescription generic, through subsidiary Morepen Bio Inc. It also filed a Sitagliptin ANDA with the US FDA.
Morepen Laboratories Management Change
Morepen Laboratories announced promotions effective 27 October 2026 for two senior management personnel. Charanjeet Chitakara moves to Assistant Vice President (Quality Control) and Vivan Prashar to Vice President (Projects & Engineering).
Morepen Laboratories Other Announcement
Morepen filed its Q2FY27 Monitoring Agency Report confirming Nil deviation in QIP proceeds utilization. The company spent ₹1.12 crore on modernization and expansion during the quarter.
Morepen Laboratories Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs755 Cr (+81%), PAT Rs89 Cr (+117%), EBITDA margin 17.45% (+897bps). H1 revenue Rs1,330 Cr (+57%). CDMO scale-up drives mix.
Morepen Laboratories Results Update
Morepen hit record Q2 FY27 revenue up 81% and EBITDA up 273%, driven by CDMO scale-up. H1 EBITDA reached ₹220 Cr; API+CDMO capacity now 614 KL.
- API + CDMO manufacturing capacity
- 614 KL